Skip to content
2000
Volume 25, Issue 3
  • ISSN: 1871-5303
  • E-ISSN: 2212-3873

Abstract

Background

Calcitonin (CT) is a sensitive serum marker of medullary thyroid carcinoma usually detected immunoassays; however, its levels are easily disturbed by several endogenous factors.

Objective

The study aimed to discuss a case of suspected interference resulting in aberrant CT values and review previous reports of CT interference.

Methods

A female patient visited our clinic with a physical ultrasound examination showing a slightly enlarged thyroid gland with small nodules. She had elevated CT levels, inconsistent with the clinical presentation and other findings. We evaluated the results by retesting using the same platform, platform validation, multiplex dilution, Polyethylene Glycol (PEG) precipitation, heterophilic blocking tubes, and RET gene analysis.

Results

Retesting CT using the same platform confirmed the high value obtained. However, serial dilution of the sample produced nonlinear results, suggesting some interference. While PEG precipitation did not significantly reduce the CT level, incubating the sample in HBTs normalized the CT value, indicating interference from heterophilic antibodies. Gene sequencing revealed no mutations.

Conclusion

In cases where elevated CT levels are inconsistent with clinical presentations and other findings, the laboratory technicians should communicate with clinicians, analyze the reasons for the inconsistent results, and use different methods to verify the results. Accurate testing provides realistic and reliable data for doctors and patients and helps to avoid unnecessary procedures.

Loading

Article metrics loading...

/content/journals/emiddt/10.2174/0118715303287794240519191720
2024-05-24
2025-01-18
Loading full text...

Full text loading...

References

  1. HaugenB.R. AlexanderE.K. BibleK.C. DohertyG.M. MandelS.J. NikiforovY.E. PaciniF. RandolphG.W. SawkaA.M. SchlumbergerM. SchuffK.G. ShermanS.I. SosaJ.A. StewardD.L. TuttleR.M. WartofskyL. 2015 American thyroid association management guidelines for adult patients with thyroid nodules and differentiated thyroid cancer: The American thyroid association guidelines task force on thyroid nodules and differentiated thyroid cancer.Thyroid2016261113310.1089/thy.2015.0020 26462967
    [Google Scholar]
  2. JaberT. DaduR. HuM.I. Medullary thyroid carcinoma.Curr. Opin. Endocrinol. Diabetes Obes.202128554054610.1097/MED.0000000000000662 34292174
    [Google Scholar]
  3. KiriakopoulosA. GiannakisP. MenenakosE. Calcitonin: Current concepts and differential diagnosis.Ther. Adv. Endocrinol. Metab.2022132042018822109934410.1177/20420188221099344 35614985
    [Google Scholar]
  4. VardarliI. WeberM. WeidemannF. FührerD. HerrmannK. GörgesR. Diagnostic accuracy of routine calcitonin measurement for the detection of medullary thyroid carcinoma in the management of patients with nodular thyroid disease: A meta-analysis.Endocr. Connect.202110335837010.1530/EC‑21‑0030 33638941
    [Google Scholar]
  5. SencarM.E. HepsenS. ÇalapkuluM. BostanH. SakizD. UnsalO.I. DugerH. KizilgulM. UcanB. TurkmenogluT.T. OzbekM. CakalE. The value of routine measurement of serum calcitonin on insufficient, indeterminate, and suspicious thyroid nodule cytology.Bosn. J. Basic Med. Sci.2022221118123 34247569
    [Google Scholar]
  6. LeimbachR.D. HoangT.D. ShakirM.K.M. Diagnostic challenges of medullary thyroid carcinoma.Oncology202199742243210.1159/000515373 33878761
    [Google Scholar]
  7. VanO.T. DemirL. Presence of macroproteins on the measurement of vitamin B12: studying high vitamin B12 levels using polyethylene glycol and heterophile antibody blocking tubes.Scand. J. Clin. Lab. Invest.202383212513210.1080/00365513.2023.2175328 36750978
    [Google Scholar]
  8. GaroM.L. CampennìA. OvcaricekP.P. D’AurizioF. GiovanellaL. Evolution of thyroid cancer biomarkers: From laboratory test to patients’ clinical management.Clin. Chem. Lab. Med.202361593594510.1515/cclm‑2022‑1087 36370420
    [Google Scholar]
  9. GhazalK. BrabantS. PrieD. PikettyM.L. Hormone immunoassay interference: A 2021 update.Ann. Lab. Med.202242132310.3343/alm.2022.42.1.3 34374345
    [Google Scholar]
  10. BraunsteinG.D. Spurious serum hormone immunoassay results: causes, recognition, management.touchREV Endocrinol.2022182141147
    [Google Scholar]
  11. RaverotV. PerrinP. ChansonP. JouanneauE. BrueT. RaverotG. Prolactin immunoassay: Does the high-dose hook effect still exist?Pituitary202225465365710.1007/s11102‑022‑01246‑8 35793045
    [Google Scholar]
  12. AlvesT.G. KasamatsuT.S. YangJ.H. MeneghettiM.C.Z. MendesA. KuniiI.S. LindseyS.C. CamachoC.P. da SilvaD.M.R. MacielR.M.B. VieiraJ.G.H. MartinsJ.R.M. Macrocalcitonin is a novel pitfall in the routine of serum calcitonin immunoassay.J. Clin. Endocrinol. Metab.2016101265365810.1210/jc.2015‑3137 26647152
    [Google Scholar]
  13. CensiS. CavedonE. FernandoS.W. BarolloS. BertazzaL. ZamboninL. ZaninottoM. FaggianD. PlebaniM. MianC. Calcitonin measurement and immunoassay interference: A case report and literature review.Clin. Chem. Lab. Med.201654121861187010.1515/cclm‑2015‑116127166721
    [Google Scholar]
  14. ZanchettaM.B. GiacoiaE. JerkovichF. FradingerE. Asymptomatic elevated parathyroid hormone level due to immunoassay interference.Osteoporos. Int.202132102111211410.1007/s00198‑021‑05950‑2 33893820
    [Google Scholar]
  15. ChaulinA.M. On the effect of heterophilic antibodies on serum levels of cardiac troponins: A Brief Descriptive Review.Life2022128111410.3390/life12081114 35892916
    [Google Scholar]
  16. SeifertP. KloosE. RitterK. FreesmeyerM. Calcitonin screening – consideration of heterophilic antibody interference in a case of obscure hypercalcitoninemia.Nucl. Med.2020591353710.1055/a‑1086‑0393 31958863
    [Google Scholar]
  17. PapapetrouP.D. PolymerisA. KargaH. VaiopoulosG. Heterophilic antibodies causing falsely high serum calcitonin values.J. Endocrinol. Invest.2006291091992310.1007/BF03349197 17185902
    [Google Scholar]
  18. UnalM.C. BayraktarA.C. UsluT. YenerS. Multiple immunoassay interference in a patient with falsely elevated calcitonin.Arch. Endocrinol. Metab.202468e23007410.20945/2359‑4292‑2023‑0074 37988668
    [Google Scholar]
  19. IsmailA.A.A. On detecting interference from endogenous antibodies in immunoassays by doubling dilutions test.Clin. Chem. Lab. Med.200745785185410.1515/CCLM.2007.152 17617026
    [Google Scholar]
  20. BolstadN. WarrenD.J. NustadK. Heterophilic antibody interference in immunometric assays.Best Pract. Res. Clin. Endocrinol. Metab.201327564766110.1016/j.beem.2013.05.011 24094636
    [Google Scholar]
  21. FukushitaM. WatanabeN. NohY.J. YoshiharaA. MatsumotoM. SuzukiN. YoshimuraR. SuginoK. ItoK. A case of macro-TSH consisting of IgA-bound TSH.Endocr. J.202168101241124610.1507/endocrj.EJ21‑0021 34039782
    [Google Scholar]
  22. LuR.M. HwangY.C. LiuI.J. LeeC.C. TsaiH.Z. LiH.J. WuH.C. Development of therapeutic antibodies for the treatment of diseases.J. Biomed. Sci.2020271110.1186/s12929‑019‑0592‑z 31894001
    [Google Scholar]
  23. IsmailA A A. Interference from endogenous antibodies in automated immunoassays: What laboratorians need to know.J. Clin. Pathol.200962867367810.1136/jcp.2008.055848 19638536
    [Google Scholar]
  24. StenmanU.H. Improving immunoassay performance by antibody engineering.Clin. Chem.200551580180210.1373/clinchem.2005.049221 15855662
    [Google Scholar]
  25. RosarioP.W. MourãoG.F. Diagnostic utility of procalcitonin for sporadic medullary thyroid carcinoma in patients with nodular disease and mild or moderate hypercalcitoninemia.Horm. Metab. Res.202254422022310.1055/a‑1773‑1127 35413742
    [Google Scholar]
  26. GiovanellaL. GiordaniI. ImperialiM. OrlandiF. TrimboliP. Measuring procalcitonin to overcome heterophilic-antibody-induced spurious hypercalcitoninemia.Clin. Chem. Lab. Med. (CCLM)2018568e191e19310.1515/cclm‑2017‑099329257751
    [Google Scholar]
  27. GiovanellaL. GaroM.L. CerianiL. PaoneG. Campenni’A. D’AurizioF. Procalcitonin as an alternative tumor marker of medullary thyroid carcinoma.J. Clin. Endocrinol. Metab.202110612dgab56410.1210/clinem/dgab564 34382653
    [Google Scholar]
/content/journals/emiddt/10.2174/0118715303287794240519191720
Loading
/content/journals/emiddt/10.2174/0118715303287794240519191720
Loading

Data & Media loading...

Supplements

Supplementary material is available on the publisher’s website along with the published article.


  • Article Type:
    Research Article
Keyword(s): Calcitonin; heterophilic antibodies; immunoassay; interference; RET mutation; thyroid cancer
This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test